Special Issue

Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine

Message from the Guest Editors

Personalized therapy is an emerging research area for disease treatment taking into account individual difference in genes, environment and lifestyles. We hope to review the recent advances and upcoming technologies that will define how we can provide personalized treatment supported by individual patient or tumor molecular features or tailored to specific patient populations through targeted drug delivery. This Special Issue will cover established, new, and upcoming potential drugs, novel diagnostic modalities and therapeutic strategies, genomic discovery, nanomedicine, and cutting-edge technologies employed at all stages of target and drug discovery, validation, and delivery. It will also explore the role of machine learning in refining the understanding of mechanisms of resistance and signaling within complex pathophysiological systems. We invite established investigators to contribute with original research and review articles. The submission deadline is May 1, 2023. Sincerely.

Dr. Benedito A. Carneiro Dr. Chong-xian Pan

Guest Editors

Prof. Dr. Liang Cheng

Dr. Benedito A. Carneiro

Dr. Chong-Xian Pan

Deadline for manuscript submissions

closed (15 November 2024)



Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/143184

Journal of Personalized Medicine Editorial Office MDPI, Grosspeteranlage 5 4052 Basel, Switzerland Tel: +41 61 683 77 34 jpm@mdpi.com

mdpi.com/journal/ jpm





Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical

subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2. Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

